CS3015

CS3015 is an experimental therapeutic candidate being developed by CStone Pharmaceuticals for the treatment of inflammatory diseases. While specific structural details are limited, it is characterized as a next-generation cell therapy that integrates CAR-T technology with a bispecific antibody component targeting Transforming Growth Factor beta (TGFβ). TGFβ is a potent immunosuppressive cytokine often upregulated in chronic inflammatory and fibrotic environments. By utilizing a CAR-T framework potentially engineered to modulate or respond to TGFβ signaling, CS3015 aims to redirect the immune response to treat severe inflammatory conditions. The program is currently in the early stages of development within CStone's pipeline.